Stock performance snapshot and business overview

Rhythm Pharmaceuticals (RYTM) has seen mixed trading recently, with the stock up 3.4% over the past day but down over the past week, month and past 3 months. Year to date, the share price is also lower.

Over a longer horizon, total return over the past year is positive, and over the past 3 and 5 years the stock shows very large cumulative gains. The current share price is US$87.61, giving the company a market value of about US$5.8b.

Rhythm focuses on treatments for rare neuroendocrine diseases. Its lead product, IMCIVREE, targets several rare genetic obesity conditions, supported by late stage clinical trials. Additional pipeline candidates include bivamelagon and RM-718, both aimed at MC4R pathway diseases.

For the most recent period provided, Rhythm reported revenue of US$217.17m from development and commercialization of therapies for patients with rare diseases, with sales coming from both the United States and international markets. The company also reported a net loss of US$207.84m.

Short term momentum looks weak, with the share price down 16.57% year to date, but long term total shareholder returns remain very strong, particularly over the past three and five years.

If Rhythm's rare disease focus has your attention, you may also want to see what else is gaining interest in healthcare, starting with 40 healthcare AI stocks

With Rhythm’s share price lower year to date but longer term returns very strong, and with the stock trading below the average analyst price target, the key question is whether this is a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 37% Undervalued

Rhythm Pharmaceuticals' most followed narrative points to a fair value of $138.20 per share compared with the last close of $87.61, framing a wide gap that hinges on how investors view future earnings power and rare disease expansion.

Upcoming potential regulatory approvals and launches for setmelanotide (IMCIVREE) in new indications like acquired hypothalamic obesity and Prader Willi syndrome, alongside expansion into younger age groups, are set to materially grow Rhythm's commercial opportunity and topline over the next several years. Extension of intellectual property protection to 2034 for the lead asset and to 2040+ for next generation compounds, along with orphan drug exclusivity incentives in the U.S. and EU, create a multi year window of strong pricing power and high net margins, protecting earnings from generic/biosimilar erosion.

Curious what justifies this kind of valuation gap? The narrative leans on rapid revenue expansion, a sharp profit margin swing, and a future earnings multiple more often associated with mature, highly profitable sectors. Want to see how those ingredients are combined to back into that $138.20 figure and the assumptions around patient growth, pricing, and profitability that sit underneath it? The full narrative lays out each step of that growth story and how it is discounted using a 7.17% rate to reach today's fair value estimate.

Result: Fair Value of $138.20 (UNDERVALUED)

However, that story depends on early stage programs and a single lead drug, so any clinical setback or sustained operating losses could quickly challenge this valuation gap.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: Rich Sales Multiple Raises the Bar

Step away from fair value models for a moment and look at what investors are already paying for Rhythm’s revenue. The stock trades on a P/S of 27.6x, far above the US Biotechs average of 10.7x and above the company’s own fair ratio estimate of 19.7x. This suggests expectations are already very high. If the story falls even slightly short, how much room is there for disappointment in that multiple?

Next Steps

With sentiment clearly split between strong past returns and a demanding valuation, it makes sense to move quickly and test the thesis against the underlying facts yourself. To see what investors are optimistic about, start by checking the 3 key rewards

Looking for more investment ideas?

If Rhythm has sparked your interest, do not stop here, broader opportunities across sectors could be just as important for your long term returns.

• Target dependable income by scanning companies with robust payouts through the 10 dividend fortresses.
• Hunt for potential mispriced opportunities using the 47 high quality undervalued stocks before the crowd pays attention.
• Prioritize resilience and sleep easier at night by focusing on the 65 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.